Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- TYRA
- Price
- 30.91
- Stock movement up
- +1.48 (5.03%)
- Company name
- Tyra Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.65B
- Ent value
- 1.61B
- Price/Sales
- 3326.07
- Price/Book
- 5.88
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 94.28%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
TYRA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3326.07 |
| Price to Book | 5.88 |
| EV to Sales | 3244.20 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 53.37M |
| EPS (TTM) | -1.87 |
| FCF per share (TTM) | -1.53 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 496.00K |
| Gross profit (TTM) | -35.00K |
| Operating income (TTM) | -125.99M |
| Net income (TTM) | -111.68M |
| EPS (TTM) | -1.87 |
| EPS (1y forward) | -2.27 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -7.06% |
| Operating margin (TTM) | -25401.21% |
| Profit margin (TTM) | -22516.94% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 61.95M |
| Net receivables | 2.20M |
| Total current assets | 281.22M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 7.04M |
| Total assets | 301.85M |
| Accounts payable | 1.99M |
| Short/Current long term debt | 5.92M |
| Total current liabilities | 15.88M |
| Total liabilities | 21.34M |
| Shareholder's equity | 280.51M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -91.11M |
| Capital expenditures (TTM) | 90.00K |
| Free cash flow (TTM) | -91.20M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -39.81% |
| Return on Assets | -37.00% |
| Return on Invested Capital | -39.75% |
| Cash Return on Invested Capital | -32.46% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 29.69 |
| Daily high | 31.43 |
| Daily low | 29.30 |
| Daily Volume | 648K |
| All-time high | 31.35 |
| 1y analyst estimate | 33.00 |
| Beta | 1.09 |
| EPS (TTM) | -1.87 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 25 Mar 2026 |
Downside potential
Loading...
Downside potential data
| TYRA | S&P500 | |
| Current price drop from All-time high | -1.40% | -0.89% |
| Highest price drop | -77.48% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -53.39% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.65B
Marketcap category
Small-cap
Description
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Employees
60
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page